$309 Million is the total value of Foresite Capital Management IV, LLC's 19 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 31.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TPTX | Sell | Turning Point Therapeutics, Inc. | $68,672,000 | -7.8% | 1,826,374 | -0.2% | 22.19% | +5.4% |
| AERI | Buy | Aerie Pharmaceuticals, Inc. | $26,925,000 | +51.9% | 1,400,900 | +133.5% | 8.70% | +73.6% |
| INSM | Sell | Insmed Incorporated | $25,217,000 | -36.9% | 1,429,518 | -8.4% | 8.15% | -27.9% |
| MDCO | Buy | The Medicines Company | $23,911,000 | +162.6% | 478,217 | +91.5% | 7.73% | +200.2% |
| ASND | Ascendis Pharma A/Ssponsored adr | $23,639,000 | -16.4% | 245,424 | 0.0% | 7.64% | -4.4% | |
| CYTK | Cytokinetics Incorporated | $21,610,000 | +1.2% | 1,898,970 | 0.0% | 6.98% | +15.7% | |
| BHVN | Sell | Biohaven Pharmaceutical Holding Company Ltd. | $17,764,000 | -5.6% | 425,794 | -0.9% | 5.74% | +8.0% |
| OPTN | Sell | OptiNose, Inc. | $15,666,000 | -12.3% | 2,238,006 | -11.3% | 5.06% | +0.3% |
| VYGR | Buy | Voyager Therapeutics, Inc. | $14,294,000 | -2.2% | 830,565 | +54.7% | 4.62% | +11.8% |
| ALEC | Sell | Alector, Inc. | $13,502,000 | -37.9% | 936,371 | -18.1% | 4.36% | -29.0% |
| MYOK | Sell | Myokardia, Inc. | $12,421,000 | -3.8% | 238,186 | -7.5% | 4.01% | +10.0% |
| FULC | New | Fulcrum Therapeutics, Inc. | $11,205,000 | – | 1,687,500 | +100.0% | 3.62% | – |
| CBAY | Sell | CymaBay Therapeutics, Inc. | $10,549,000 | -42.7% | 2,060,268 | -19.9% | 3.41% | -34.5% |
| ORTX | New | Orchard Therapeutics PLCads | $6,625,000 | – | 557,700 | +100.0% | 2.14% | – |
| RYTM | Sell | Rhythm Pharmaceuticals, Inc. | $5,062,000 | -51.0% | 234,482 | -50.1% | 1.64% | -44.0% |
| IMMU | Sell | Immunomedics, Inc. | $4,875,000 | -8.9% | 367,636 | -4.7% | 1.58% | +4.2% |
| SIBN | SI-BONE, Inc. | $3,633,000 | -13.1% | 205,621 | 0.0% | 1.17% | -0.7% | |
| AERI | Aerie Pharmaceuticals, Inc.put | $1,932,000 | -34.9% | 100,500 | 0.0% | 0.62% | -25.6% | |
| AERI | Aerie Pharmaceuticals, Inc.call | $1,932,000 | -34.9% | 100,500 | 0.0% | 0.62% | -25.6% | |
| KNSA | Exit | Kiniksa Pharmaceuticals, Ltd. | $0 | – | -63,922 | -100.0% | -0.24% | – |
| ABUS | Exit | Arbutus Biopharma Corporation | $0 | – | -608,151 | -100.0% | -0.36% | – |
| VCYT | Exit | Veracyte, Inc. | $0 | – | -200,000 | -100.0% | -1.61% | – |
| NGM | Exit | NGM Biopharmaceuticals, Inc. | $0 | – | -471,269 | -100.0% | -1.95% | – |
| REPL | Exit | Replimune Group, Inc. | $0 | – | -1,228,656 | -100.0% | -5.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
| Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
| Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
| Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
| Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
| Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
| Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
| Insmed Incorporated | 10 | Q1 2020 | 19.2% |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-02-22 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.